ETP-ALL (Early T-Cell Precursor Acute Lymphoblastic Leukaemia) — Multiple Treatment Failures Including CAR-T, Repeated Bone Marrow and Extramedullary Relapse, Haploidentical Parent-Donor Transplant in China After Exhausting Local Options in Australia: A Patient Story for International Families Facing High-Risk or Relapsed Paediatric Leukaemia With Limited Remaining Treatment Pathways

A Rare and Aggressive Diagnosis

In March 2025, Jake was diagnosed in Melbourne with Early T-Cell Precursor Acute Lymphoblastic Leukaemia (ETP-ALL) — a rare, high-risk subtype characterised by rapid progression and a significantly elevated risk of treatment failure. He was fourteen years old.

His local team moved quickly. He received multiple rounds of chemotherapy, then targeted therapy. When neither achieved lasting remission, they turned to CAR-T cell therapy — one of the most advanced options available. Leukaemia came back after that too.

The relapses were not confined to the bone marrow. Jake developed disease at multiple extramedullary sites — meaning it had spread beyond the marrow to other parts of the body. Each relapse left the treating team with fewer options than before.

The accumulated burden of treatment had also left him with severe peripheral neuropathy in both feet — a side effect of chemotherapy that made walking painful and difficult. He was physically depleted, and the windows of stability between treatment cycles were getting shorter.

The Search — and What the Parents Found

The local team advised that haematopoietic stem cell transplantation was the remaining curative option. Their recommendation was a matched sibling donor transplant — Jake's younger brother, who had accompanied the family throughout treatment, was a potential donor.

The family accepted the recommendation but had reservations about relapse risk. Given Jake's history — failure across multiple treatment lines, including CAR-T — they wanted to know whether any approach offered a meaningfully lower chance of the disease coming back after transplant.

They started searching online. What they found was a substantial body of published research from China on haploidentical transplantation — using a parent as a half-matched donor — via what is known as the Beijing Protocol. The published data suggested lower relapse rates in high-risk and refractory leukaemia compared to conventional matched donor approaches.

That research led them to a specialist paediatric haematology centre in Beijing with an extensive track record in complex transplant cases. The family — Jake, his parents, and his younger brother — booked flights from Melbourne to Beijing.

December 2025: Arriving in Beijing

Jake and his family arrived on December 21, 2025. The specialist team conducted a comprehensive clinical assessment — reviewing his full treatment history, current disease status, organ function, neurological condition, and the available donor options.

What the team found was a complicated picture: multiple prior treatment failures, significant nerve damage, physical deconditioning, gastrointestinal problems — all on top of active leukaemia. Even so, the team reached a clear consensus. Stem cell transplantation was the only realistic path to remission, and they recommended moving forward as soon as conditioning could begin.

After a full multidisciplinary review, the team also revised the donor approach. Rather than proceeding with the matched sibling transplant that had been recommended in Australia, they proposed using Jake's father — a haploidentical, HLA 6/10 matched donor. The Beijing Protocol had extensive published data supporting this approach in high-risk paediatric cases, and the team believed it gave Jake the best chance of durable remission.

The family went through the plan carefully with the team. They signed the consent documents. They had come looking for a different answer. They had found one.

The Transplant — One Step at a Time

Conditioning began on December 30, 2025. Given the sites of extramedullary relapse, the protocol included whole-brain and whole-spinal-cord radiation, testicular radiation, and a chemotherapy course designed around Jake's specific disease profile and current organ function.

By day +10, neutrophil counts had climbed to the threshold that confirmed engraftment — the transplanted cells were taking hold. In the weeks that followed, Jake developed mild acute graft-versus-host disease affecting his skin — an expected complication with haploidentical transplants — and a transient CMV infection at around day +23. The team caught both early and managed them without lasting effect.

Inside the Ward: Care Across a Language Barrier

Jake's family could manage basic Mandarin, but the daily demands of a transplant unit — medication changes, consent conversations, symptom reporting — were a different matter entirely. Everyone on both sides knew this from day one.

Nurses adapted. They used simple vocabulary, hand gestures, and drawings to communicate care instructions and explain procedures. Doctors on ward rounds spoke slowly, repeated key points, and confirmed understanding before moving on.

The hospital's social work team and international affairs office handled the practical side of daily life — navigating payment processes, sourcing food Jake could tolerate, working through the administrative details that pile up during a long inpatient admission. "We bought him food. We helped with all the paperwork. We treated him like our own," one staff member later reflected.

The Bone Marrow Checks, the Recovering Feet, and the Flight Home

Bone marrow assessments at one, two, and three months post-transplant all came back with the same result: complete remission, MRD negative, and donor cell chimerism holding above 99%. His father's stem cells had taken root — a new immune system was being built from the ground up.

The neuropathy in Jake's feet began to ease as well. Progress was slow — first standing without support, then tentative steps, then walking with growing steadiness. The nerve damage from months of aggressive chemotherapy was never going to disappear quickly, but the direction was unmistakably upward.

In late April 2026, Jake and his family boarded a flight back to Melbourne. His younger brother — who had made the entire journey to Beijing alongside the family — was waiting at the airport when they landed.

Before the Flight: "Please Pass On Our Thanks"

On the evening before they left, Jake's grandmother sent a long message of thanks. His mother had one request: that her gratitude reach every person who had played any part in their time in Beijing — the doctors, the nurses, the social workers, the international patient team, everyone.

The message arrived in simple language. It did not require translation to be understood.